One-Month SOFR Futures (SR1 June 2025)/ XFTTSR1CMEGL / CME GLOBEX
SR1| 6/24/2025 9:41:22 PM | Chg. +0.0025 | Bid10:02:22 PM | Ask10:02:10 PM | Open | High | Low | Previous Close |
|---|---|---|---|---|---|---|---|
| 95.6950USD | 0.00% | 95.6925 | 95.6950 | 95.6925 | 95.6950 | 95.6925 | 95.6925 |
GlobeNewswire
3/24
Sermonix and Regor Announce Strategic Collaboration to Optimize Regor’s Proprietary rCARD Platform f...
Newsfile Corp
11/4/2024
Sekuya Racing Secures Third Straight Win at Mandalika Festival of Speed 2024
Newsfile Corp
10/14/2024
Sekuya Racing and Neiro Gear Up for Radical Time Attack 2 with Senna Iriawan at Mandalika
GlobeNewswire
7/18/2024
Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resi...
GlobeNewswire
6/10/2024
Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifen...
GlobeNewswire
6/6/2024
Sermonix Pharmaceuticals Announces Chinese Approval of Investigational New Drug Application for Laso...
Newsfile Corp
6/6/2024
First Fence Enhances Property Security with LPS 1175 Rated ProFence(R) SR1 System
GlobeNewswire
5/30/2024
Sermonix Pharmaceuticals to Present Poster on ELAINE-3 Trial in Progress at ASCO 2024
GlobeNewswire
4/29/2024
Sermonix Pharmaceuticals Announces ‘Menopause’ Journal Publication of Article on Oral Lasofoxifene’s...
GlobeNewswire
12/12/2023
Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE La...
GlobeNewswire
12/12/2023
Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient...
GlobeNewswire
11/6/2023
Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete R...
GlobeNewswire
12/13/2021
Sermonix Pharmaceuticals Announces Poster Presentation at the 2021 San Antonio Breast Cancer Symposi...
GlobeNewswire
11/15/2021
Sermonix Pharmaceuticals Closes $40 Million Series A3 Financing Round Led by Perceptive Xontogeny Ve...
GlobeNewswire
8/16/2021
Sermonix Pharmaceuticals Completes Enrollment of Phase 2 ELAINE 1 Randomized Clinical Trial Assessin...
GlobeNewswire
6/28/2021
Sermonix Pharmaceuticals Completes Enrollment of Phase 2 Clinical Trial Collaboration Studying Lasof...
GlobeNewswire
4/21/2021
Sermonix Pharmaceuticals Project With Huntsman Cancer Institute Researcher to Investigate Potential ...
GlobeNewswire
12/3/2020
Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Compan...
GlobeNewswire
10/13/2020
Sermonix Doses First Patient in Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combin...
GlobeNewswire
9/30/2020
Sermonix Pharmaceuticals Partners With Exactis Innovation for ELAINE 1 Clinical Trial Sites in Canad...
GlobeNewswire
7/8/2020
Sermonix Pharmaceuticals to Collaborate With Eli Lilly and Company in Studying Combination of Lasofo...
GlobeNewswire
9/25/2019
Sermonix to Present Poster on Oncologists’ Perception of Sexual Intimacy Issues in Treatment of Meta...
GlobeNewswire
9/23/2019
Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medici...
GlobeNewswire
7/31/2019
Sermonix Pharmaceuticals Closes US$26 Million Series A Financing Round Led by WILD Family Office
